relapsed
Showing 1 - 5 of 5
Leukemia, Relapsed, Myeloid Trial in Netherlands, Switzerland (MP0533 (multispecific DARPin CD3 Engager Targeting CD33, CD123
Recruiting
- Leukemia
- +3 more
- MP0533 (multispecific DARPin CD3 Engager Targeting CD33, CD123 and CD70)
-
Amsterdam, Netherlands
- +4 more
Jan 4, 2023
Chronic Lymphocytic Leukemia (CLL), Relapsed, Refractory Trial in New York (EGFRt/19-28z/4-1BBL CAR T cells)
Active, not recruiting
- Chronic Lymphocytic Leukemia (CLL)
- +2 more
- EGFRt/19-28z/4-1BBL CAR T cells
-
New York, New YorkMemorial Sloan Kettering Cancer Center
Apr 1, 2022
Identify Barriers to Allogeneic Hematopoietic Stem Cell
Recruiting
- Acute Leukemia
- +2 more
- assessments
-
Hartford, Connecticut
- +2 more
Jan 21, 2022
Refractory, Relapsed, B Cell Lymphoma Trial in Zhengzhou (CAR-T cells)
Unknown status
- Refractory
- +3 more
- CAR-T cells
-
Zhengzhou, Henan, China
- +1 more
Mar 19, 2019
B-Cell Lymphoma Stage I, Refractory, Relapsed Trial in Zhengzhou (CD19/CD20 bispecific CAR-T cells)
Unknown status
- B-Cell Lymphoma Stage I
- +2 more
- CD19/CD20 bispecific CAR-T cells
-
Zhengzhou, Henan, China
- +1 more
Mar 19, 2019